News

Fierce Pharma3d
Novo offers Wegovy discount for new patients, launches new ad campaign as time runs out for compounders
It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...
BioPharma Dive3d
Novo pressures GLP-1 compounders as FDA ban takes hold
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...
Yahoo Finance3d
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...
Why Novo Nordisk Stock Popped on Tuesday
Novo Nordisk ( NVO -1.33%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...
Novo Nordisk joins finance’s great one-hit wonders
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Pharmaceutical Technology on MSN6d
Novo Nordisk’s CEO to step down as weight loss market share plummets
Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...
Novo Nordisk announces CEO transition as share price slips
Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...